Core Insights - 60 Degrees Pharmaceuticals is addressing the rising threat of babesiosis, a tick-borne disease, through participation in the Healing Lyme Summit [1][2][4] - The company is conducting two active clinical trials to evaluate the efficacy and safety of tafenoquine for treating severe babesiosis [3][6] Company Overview - 60 Degrees Pharmaceuticals, founded in 2010, focuses on developing treatments for infectious diseases and achieved FDA approval for its lead product, ARAKODA® (tafenoquine), in 2018 [6] - The company collaborates with research organizations in the U.S., Australia, and Singapore, and has received support from the U.S. Department of Defense and private investors [6] Industry Context - Babesiosis is increasingly recognized as a significant public health threat, often co-occurring with Lyme disease, yet awareness and clinical recognition remain limited [2][4] - The Healing Lyme Summit, taking place from April 15–21, 2025, aims to enhance understanding and response to tick-borne illnesses through scientific discussions and educational content [4]
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21